#obesity-treatment

#obesity-treatment

Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a recent study, showing superior weight loss and waist circumference reduction.

Orforglipron, a new oral GLP-1 drug from Eli Lilly, may transform obesity treatment by offering a non-injection alternative.

GLP-1's discovery has revolutionized the treatment of obesity and diabetes.

Unexpected research paths can lead to significant medical advancements.

Ozempic drugs show promise in treating fatty liver disease, halting or reversing its progression, and may provide broader therapeutic effects beyond weight loss.

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.

Pfizer has halted the development of danuglipron due to safety concerns, but remains committed to exploring other obesity treatment options.

Trump administration's decision excludes expensive obesity treatments from Medicare coverage.

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.

GLP-1 receptor agonists show potential in reducing alcohol cravings but safety for non-obese individuals remains uncertain.